These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25926715)

  • 1. Role of biologics in intractable urticaria.
    Cooke A; Bulkhi A; Casale TB
    Biologics; 2015; 9():25-33. PubMed ID: 25926715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics in Chronic Urticaria.
    Bulkhi A; Cooke AJ; Casale TB
    Immunol Allergy Clin North Am; 2017 Feb; 37(1):95-112. PubMed ID: 27886913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Expanding Field of Biologics in the Management of Chronic Urticaria.
    Joshi S; Khan DA
    J Allergy Clin Immunol Pract; 2017; 5(6):1489-1499. PubMed ID: 28734860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
    Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
    BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine.
    Curto-Barredo L; Giménez-Arnau AM
    G Ital Dermatol Venereol; 2019 Aug; 154(4):444-456. PubMed ID: 30717573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experiences with omalizumab for the treatment of chronic urticaria.
    Sussman G; Hébert J; Barron C; Bian J; Caron-Guay RM; Laflamme S; Stern S
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):170-4. PubMed ID: 24468258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New biologics in the treatment of urticaria.
    Kocatürk E; Zuberbier T
    Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):425-431. PubMed ID: 30015639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic Therapy in the Treatment of Chronic Skin Disorders.
    Fernandez JM; Fernandez AP; Lang DM
    Immunol Allergy Clin North Am; 2017 May; 37(2):315-327. PubMed ID: 28366479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab in chronic urticaria: our experience and literature review.
    Košnik M; Kopač P; Eržen R; Bajrović N; Adamič K; Lalek N; Korošec P; Zidarn M
    Acta Dermatovenerol Alp Pannonica Adriat; 2014; 23(3):57-61. PubMed ID: 25242162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologicals in Treatment of Chronic Urticaria: A Narrative Review.
    Mustari AP; Bishnoi A; Kumaran MS
    Indian Dermatol Online J; 2023; 14(1):9-20. PubMed ID: 36776192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of omalizumab on patients with chronic urticaria.
    Spector SL; Tan RA
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):190-3. PubMed ID: 17718108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges and controversies in the management of chronic spontaneous urticaria.
    Asero R; Pinter E; Marra AM; Tedeschi A; Cugno M; Marzano AV
    Expert Rev Clin Immunol; 2015; 11(10):1073-82. PubMed ID: 26174347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab is efficacious for management of recalcitrant, antihistamine-resistant chronic urticaria.
    Lang DM
    Drugs Today (Barc); 2015 Jun; 51(6):367-74. PubMed ID: 26261850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin as a potential therapy for refractory urticaria - a review.
    Watkins C; Peiris E; Saleh H; Krishnaswamy G
    Inflamm Allergy Drug Targets; 2012 Oct; 11(5):375-81. PubMed ID: 22594611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in the treatment of chronic urticaria.
    Francés L; Leiva-Salinas M; Silvestre JF
    Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab.
    Uysal P; Erge D
    Turk Pediatri Ars; 2018 Dec; 53(4):250-254. PubMed ID: 30872928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic recurrent wheals - If not chronic spontaneous urticaria, what else?
    Bonnekoh H; Krause K; Kolkhir P
    Allergol Select; 2023; 7():8-16. PubMed ID: 36644011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.